Autolus Therapeutics' AUCATZYL Granted EU Marketing Authorization for R/R B-ALL Treatment

Autolus Therapeutics' CAR T therapy AUCATZYL (Obecabtagene Autoleucel) has been granted European Marketing Authorization for adult patients (age 26 and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL). The approval is based on the FELIX clinical trial, which demonstrated high and durable response rates and low toxicity.